Daptomycin therapy for invasive Gram-positive bacterial infections in children

Monica I. Ardura, Asunción Mejías, Kathy S. Katz, Paula Revell, George H. McCracken, Pablo J. Sánchez

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

BACKGROUND: Clinical improvement is often delayed among children with invasive infections caused by multidrug resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) despite use of standard antimicrobial therapy. Daptomycin, a bactericidal lipopeptide antibiotic, may prove useful for treatment of these infections in children, but clinical experience is lacking. METHODS: Retrospective review of medical records of hospitalized children who received daptomycin for treatment of invasive Gram-positive bacterial infections at Children's Medical Center Dallas from December 2003 to March 2007. Bacterial isolates were tested for susceptibility to daptomycin and characterized by pulsed-field gel electrophoresis and polymerase chain reaction for staphylococcal cassette chromosome mec A. RESULTS: Sixteen children (10 male; median age, 6.5 years) received daptomycin. Fifteen (94%) children had invasive staphylococcal disease (14, MRSA, of which 13 were community-associated; 1, methicillin-susceptible S. aureus), and 1 had urinary tract infection caused by VRE. Twelve children with disseminated staphylococcal disease had bacteremia for 2-10 days despite therapy with 2 or more of the following: vancomycin, clindamycin, rifampin, aminoglycoside, or linezolid. The addition of daptomycin resulted in bacteriologic cure in 6 of 7 evaluable patients with persistent bacteremia. No adverse events were attributed to daptomycin. Overall, 14 patients improved and were discharged home, and 2 died of complications of their underlying medical conditions. CONCLUSIONS: The majority of patients demonstrated clinical improvement after addition of daptomycin to conventional antimicrobial therapy. Further studies are needed to assess the pharmacokinetics, pharmacodynamics, safety, and effectiveness of daptomycin in infants and children.

Original languageEnglish (US)
Pages (from-to)1128-1132
Number of pages5
JournalPediatric Infectious Disease Journal
Volume26
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Gram-Positive Bacterial Infections
Daptomycin
Linezolid
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Bacteremia
Lipopeptides
Methicillin
Hospitalized Child
Clindamycin
Pulsed Field Gel Electrophoresis
Gram-Positive Bacteria
Aminoglycosides
Vancomycin
Rifampin
Infection
Urinary Tract Infections
Medical Records
Staphylococcus aureus
Pharmacokinetics

Keywords

  • Children
  • Daptomycin
  • MRSA
  • Staphylococcus aureus
  • VRE

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Daptomycin therapy for invasive Gram-positive bacterial infections in children. / Ardura, Monica I.; Mejías, Asunción; Katz, Kathy S.; Revell, Paula; McCracken, George H.; Sánchez, Pablo J.

In: Pediatric Infectious Disease Journal, Vol. 26, No. 12, 12.2007, p. 1128-1132.

Research output: Contribution to journalArticle

Ardura, Monica I. ; Mejías, Asunción ; Katz, Kathy S. ; Revell, Paula ; McCracken, George H. ; Sánchez, Pablo J. / Daptomycin therapy for invasive Gram-positive bacterial infections in children. In: Pediatric Infectious Disease Journal. 2007 ; Vol. 26, No. 12. pp. 1128-1132.
@article{b28eedb9dcf84dfe99b1b673b0d2e646,
title = "Daptomycin therapy for invasive Gram-positive bacterial infections in children",
abstract = "BACKGROUND: Clinical improvement is often delayed among children with invasive infections caused by multidrug resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) despite use of standard antimicrobial therapy. Daptomycin, a bactericidal lipopeptide antibiotic, may prove useful for treatment of these infections in children, but clinical experience is lacking. METHODS: Retrospective review of medical records of hospitalized children who received daptomycin for treatment of invasive Gram-positive bacterial infections at Children's Medical Center Dallas from December 2003 to March 2007. Bacterial isolates were tested for susceptibility to daptomycin and characterized by pulsed-field gel electrophoresis and polymerase chain reaction for staphylococcal cassette chromosome mec A. RESULTS: Sixteen children (10 male; median age, 6.5 years) received daptomycin. Fifteen (94{\%}) children had invasive staphylococcal disease (14, MRSA, of which 13 were community-associated; 1, methicillin-susceptible S. aureus), and 1 had urinary tract infection caused by VRE. Twelve children with disseminated staphylococcal disease had bacteremia for 2-10 days despite therapy with 2 or more of the following: vancomycin, clindamycin, rifampin, aminoglycoside, or linezolid. The addition of daptomycin resulted in bacteriologic cure in 6 of 7 evaluable patients with persistent bacteremia. No adverse events were attributed to daptomycin. Overall, 14 patients improved and were discharged home, and 2 died of complications of their underlying medical conditions. CONCLUSIONS: The majority of patients demonstrated clinical improvement after addition of daptomycin to conventional antimicrobial therapy. Further studies are needed to assess the pharmacokinetics, pharmacodynamics, safety, and effectiveness of daptomycin in infants and children.",
keywords = "Children, Daptomycin, MRSA, Staphylococcus aureus, VRE",
author = "Ardura, {Monica I.} and Asunci{\'o}n Mej{\'i}as and Katz, {Kathy S.} and Paula Revell and McCracken, {George H.} and S{\'a}nchez, {Pablo J.}",
year = "2007",
month = "12",
doi = "10.1097/INF.0b013e31814523f8",
language = "English (US)",
volume = "26",
pages = "1128--1132",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Daptomycin therapy for invasive Gram-positive bacterial infections in children

AU - Ardura, Monica I.

AU - Mejías, Asunción

AU - Katz, Kathy S.

AU - Revell, Paula

AU - McCracken, George H.

AU - Sánchez, Pablo J.

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND: Clinical improvement is often delayed among children with invasive infections caused by multidrug resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) despite use of standard antimicrobial therapy. Daptomycin, a bactericidal lipopeptide antibiotic, may prove useful for treatment of these infections in children, but clinical experience is lacking. METHODS: Retrospective review of medical records of hospitalized children who received daptomycin for treatment of invasive Gram-positive bacterial infections at Children's Medical Center Dallas from December 2003 to March 2007. Bacterial isolates were tested for susceptibility to daptomycin and characterized by pulsed-field gel electrophoresis and polymerase chain reaction for staphylococcal cassette chromosome mec A. RESULTS: Sixteen children (10 male; median age, 6.5 years) received daptomycin. Fifteen (94%) children had invasive staphylococcal disease (14, MRSA, of which 13 were community-associated; 1, methicillin-susceptible S. aureus), and 1 had urinary tract infection caused by VRE. Twelve children with disseminated staphylococcal disease had bacteremia for 2-10 days despite therapy with 2 or more of the following: vancomycin, clindamycin, rifampin, aminoglycoside, or linezolid. The addition of daptomycin resulted in bacteriologic cure in 6 of 7 evaluable patients with persistent bacteremia. No adverse events were attributed to daptomycin. Overall, 14 patients improved and were discharged home, and 2 died of complications of their underlying medical conditions. CONCLUSIONS: The majority of patients demonstrated clinical improvement after addition of daptomycin to conventional antimicrobial therapy. Further studies are needed to assess the pharmacokinetics, pharmacodynamics, safety, and effectiveness of daptomycin in infants and children.

AB - BACKGROUND: Clinical improvement is often delayed among children with invasive infections caused by multidrug resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) despite use of standard antimicrobial therapy. Daptomycin, a bactericidal lipopeptide antibiotic, may prove useful for treatment of these infections in children, but clinical experience is lacking. METHODS: Retrospective review of medical records of hospitalized children who received daptomycin for treatment of invasive Gram-positive bacterial infections at Children's Medical Center Dallas from December 2003 to March 2007. Bacterial isolates were tested for susceptibility to daptomycin and characterized by pulsed-field gel electrophoresis and polymerase chain reaction for staphylococcal cassette chromosome mec A. RESULTS: Sixteen children (10 male; median age, 6.5 years) received daptomycin. Fifteen (94%) children had invasive staphylococcal disease (14, MRSA, of which 13 were community-associated; 1, methicillin-susceptible S. aureus), and 1 had urinary tract infection caused by VRE. Twelve children with disseminated staphylococcal disease had bacteremia for 2-10 days despite therapy with 2 or more of the following: vancomycin, clindamycin, rifampin, aminoglycoside, or linezolid. The addition of daptomycin resulted in bacteriologic cure in 6 of 7 evaluable patients with persistent bacteremia. No adverse events were attributed to daptomycin. Overall, 14 patients improved and were discharged home, and 2 died of complications of their underlying medical conditions. CONCLUSIONS: The majority of patients demonstrated clinical improvement after addition of daptomycin to conventional antimicrobial therapy. Further studies are needed to assess the pharmacokinetics, pharmacodynamics, safety, and effectiveness of daptomycin in infants and children.

KW - Children

KW - Daptomycin

KW - MRSA

KW - Staphylococcus aureus

KW - VRE

UR - http://www.scopus.com/inward/record.url?scp=36549005621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549005621&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e31814523f8

DO - 10.1097/INF.0b013e31814523f8

M3 - Article

C2 - 18043450

AN - SCOPUS:36549005621

VL - 26

SP - 1128

EP - 1132

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -